TORONTO, Sept. 17, 2007 (PRIME NEWSWIRE) -- Cannasat Therapeutics Inc. ("Cannasat") (TSX-V:CTH), a company specializing in the development of cannabinoid-based pharmaceutical products, announced today the commencement of a Phase 1 clinical study of its lead product, CAT 310, a potential treatment for neuropathic pain.
